{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:38Z","timestamp":1790720378299,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Recent data demonstrate that one possibility for increasing Peptide Receptor Radionuclide Therapy (PRRT) results lies in the combination of PRRT with chemotherapy. This study aimed to evaluate response and outcome in [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-positive metastatic neuroendocrine tumor (mNET) patients treated with PRRT alone or in combination with temozolomide (TEM) plus\/minus capecitabine (CAP).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All mNET patients presented with [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG-positive disease prior to treatment (or retreatment) with PRRT alone or in combination with chemotherapy were retrospectively included in this single-center study. Patients received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE with an activity of 7.4 GBq alone or combined with TEM (200\u00a0mg\/kg\/5d) plus\/minus CAP (1500\u00a0mg\/kg\/14d). Contrast-enhancement CT (ceCT), [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTATOC and [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT studies were performed at baseline, after treatment, and every 6 months thereafter. Overall response rate (ORR) and disease control rate (DCR) were calculated for each group. Survival analysis was performed using the Kaplan-Meier method. Adverse events were collected and classified according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 24 patients were included in the final analysis. Group 1 received PRRT with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910), group 2 received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE plus TEM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097), and group 3 received [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE plus CAPTEM (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). There were no differences between groups in terms of clinicopathological features before treatment. The pancreas was the primary tumor site in 58%, and 92% of patients had more than three liver metastases. Based on [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-DOTATOC PET\/CT and ceCT, in group 1 the ORR and DCR were 10% and 50%, respectively. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT showed 2 responders (1 CR, 1 PR). In group 2, the ORR and DCR were 14% and 43%, respectively. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT showed 2 responders (1 CR, 1 PR). In group 3, the ORR and DCR were 71%, respectively. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT showed 5 responders (3 CR, 2 PR). In the latter group, 4\/7 patients had not progressed and 5\/7 were still alive at the time of analysis after a median follow-up of 31 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results show PRRT combined with CAPTEM as the most promising regimen, achieving higher response rates in [\u00b9\u2078F]FDG-positive mNETs compared with PRRT alone or PRRT plus TEM. Further studies are required to confirm its added value in terms of survival outcomes. No increased toxicity seems to be associated with combination therapy compared to PRRT alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07606-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:17:50Z","timestamp":1761016670000},"page":"1927-1938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peptide receptor radionuclide therapy alone or in combination with temozolomide plus\/minus capecitabine in [18F]FDG-positive metastatic neuroendocrine tumors"],"prefix":"10.1007","volume":"53","author":[{"given":"Gianpaolo","family":"di Santo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-0686","authenticated-orcid":false,"given":"Giulia","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Kronthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Djanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7097-6170","authenticated-orcid":false,"given":"Irene J.","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"7","key":"7606_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, et al. NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60(7):937\u201343.","journal-title":"J Nucl Med"},{"issue":"2","key":"7606_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"7606_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"10446","key":"7606_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317.","journal-title":"Lancet"},{"issue":"3","key":"7606_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70013","volume":"37","author":"G Santo","year":"2025","unstructured":"Santo G, di Santo G, Cicone F, Virgolini I. Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. J Neuroendocrinol. 2025;37(3):e70013. https:\/\/doi.org\/10.1111\/jne.70013.","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"7606_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","volume":"32","author":"E Baudin","year":"2021","unstructured":"Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32(4):439\u201351. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.003.","journal-title":"Ann Oncol"},{"issue":"10","key":"7606_CR7","doi-asserted-by":"publisher","first-page":"103664","DOI":"10.1016\/j.esmoop.2024.103664","volume":"9","author":"J Hadoux","year":"2024","unstructured":"Hadoux J, Lamarca A, Grande E, et al. Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2024;9(10):103664. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103664.","journal-title":"ESMO Open"},{"key":"7606_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.01.008","volume":"146","author":"V Ambrosini","year":"2021","unstructured":"Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56\u201373.","journal-title":"Eur J Cancer"},{"issue":"3","key":"7606_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","volume":"46","author":"WA van der Zwan","year":"2019","unstructured":"van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46(3):704\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7606_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102141","volume":"93","author":"J Strosberg","year":"2021","unstructured":"Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis [published correction appears in Cancer Treat Rev. 2021;97:102203]. Cancer Treat Rev. 2021;93:102141.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"7606_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.semnuclmed.2015.12.003","volume":"46","author":"L Bodei","year":"2016","unstructured":"Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46(3):225\u201338.","journal-title":"Semin Nucl Med"},{"key":"7606_CR12","doi-asserted-by":"crossref","unstructured":"Strosberg JR, Caplin ME, Kunz PL et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial [published correction appears in Lancet Oncol. 2022;23(2):e59]. Lancet Oncol. 2021;22(12):1752\u20131763.","DOI":"10.1016\/S1470-2045(21)00572-6"},{"issue":"6","key":"7606_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061861","volume":"15","author":"I Reccia","year":"2023","unstructured":"Reccia I, Pai M, Kumar J, Spalding D, Frilling A. Tumour heterogeneity and the consequent practical challenges in the management of gastroenteropancreatic neuroendocrine neoplasms. Cancers (Basel). 2023;15(6):1861.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"7606_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup T, Knigge U, Johnbeck CB, et al. 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study. J Nucl Med. 2021;62(6):808\u201315.","journal-title":"J Nucl Med"},{"issue":"11","key":"7606_CR15","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","volume":"55","author":"H Bahri","year":"2014","unstructured":"Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55(11):1786\u201390.","journal-title":"J Nucl Med"},{"issue":"3","key":"7606_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","volume":"16","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978\u201385.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"7606_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","volume":"41","author":"G Paganelli","year":"2014","unstructured":"Paganelli G, Sansovini M, Ambrosetti A, et al. 177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7606_CR18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2967\/jnumed.108.057505","volume":"50","author":"E Garin","year":"2009","unstructured":"Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50(6):858\u201364.","journal-title":"J Nucl Med"},{"issue":"6","key":"7606_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095\u2013111. https:\/\/doi.org\/10.1016\/j.molonc.2014.06.005.","journal-title":"Mol Oncol"},{"issue":"8","key":"7606_CR20","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s00259-014-2805-8","volume":"41","author":"S Basu","year":"2014","unstructured":"Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging. 2014;41(8):1492\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7606_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13423","volume":"36","author":"A Lamarca","year":"2024","unstructured":"Lamarca A, Bartsch DK, Caplin M, et al. European neuroendocrine tumor society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours. J Neuroendocrinol. 2024;36(9):e13423.","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"7606_CR22","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","volume":"59","author":"TM Pawlik","year":"2004","unstructured":"Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"7606_CR23","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00259-021-05330-2","volume":"48","author":"F Minutoli","year":"2021","unstructured":"Minutoli F, Laudicella R, Burger IA, Baldari S. Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging. Eur J Nucl Med Mol Imaging. 2021;48(10):3041\u20132. https:\/\/doi.org\/10.1007\/s00259-021-05330-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7606_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/0360-3016(79)90634-5","volume":"5","author":"Terminology in the description of drug-radiation interactions","year":"1979","unstructured":"Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys. 1979;5(8):1145\u201350. https:\/\/doi.org\/10.1016\/0360-3016(79)90634-5.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"7606_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.7150\/thno.91268","volume":"14","author":"G di Santo","year":"2024","unstructured":"di Santo G, Santo G, Sviridenko A, Virgolini I. Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023. Theranostics. 2024;14(3):940\u201353.","journal-title":"Theranostics"},{"issue":"61","key":"7606_CR26","doi-asserted-by":"publisher","first-page":"104046","DOI":"10.18632\/oncotarget.22001","volume":"8","author":"DH Owen","year":"2017","unstructured":"Owen DH, Alexander AJ, Konda B, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget. 2017;8(61):104046\u201356.","journal-title":"Oncotarget"},{"issue":"2","key":"7606_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","volume":"38","author":"PG Claringbold","year":"2011","unstructured":"Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38(2):302\u201311.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"7606_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/cbr.2012.1276","volume":"27","author":"PG Claringbold","year":"2012","unstructured":"Claringbold PG, Price RA, Turner JH. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561\u20139. https:\/\/doi.org\/10.1089\/cbr.2012.1276.","journal-title":"Cancer Biother Radiopharm."},{"key":"7606_CR29","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1200\/JCO.2022.40.16_suppl.4122","volume":"40","author":"N Pavlakis","year":"2022","unstructured":"Pavlakis N, Randsom D, Wyld D, Sjoquist K, Wilson K, Gebski V, et al. Australasian Gastrointestinal trials group (AGITG) CONTROL NET study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus Temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)\u2014Final results. J Clin Oncol. 2022;40:4122\u20134122.","journal-title":"J Clin Oncol"},{"key":"7606_CR30","unstructured":"Capecitabine on Temozolomide radionuclide therapy octreotate Lutetium-. 177 neuroendocrine tumours study (CONTROL NETS). NCT02358356. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02358356"},{"issue":"23","key":"7606_CR31","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","volume":"284","author":"World Medical Association","year":"2000","unstructured":"World Medical Association. Declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284(23):3043\u20135.","journal-title":"JAMA"},{"key":"7606_CR32","unstructured":"Arzneimittelgesetz BGB. Nr. 185\/1983, last revision BGBl. II Nr. 105\/2015. https:\/\/www.ris.bka.gv.at\/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10010441"},{"key":"7606_CR33","unstructured":"\u00d6sterreichischer Verband f\u00fcr Strahlenschutz. Mitgliedsgesellschaft der International Radiation Protection Association. http:\/\/www.strahlenschutzverband.at\/index.php?id=strahlenschutzrecht0"},{"key":"7606_CR34","unstructured":"Common Terminology Criteria for Adverse Events. (CTCAE v5.0). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"issue":"4","key":"7606_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","volume":"128","author":"DL Chan","year":"2023","unstructured":"Chan DL, Hayes AR, Karfis I, et al. Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score. Br J Cancer. 2023;128(4):549\u201355.","journal-title":"Br J Cancer"},{"issue":"5","key":"7606_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.semnuclmed.2025.04.005","volume":"55","author":"M Di Franco","year":"2025","unstructured":"Di Franco M, Lamberti G, Campana D, Ambrosini V. Molecular imaging for response assessment of neuroendocrine tumors (NET). Semin Nucl Med. 2025;55(5):754\u201365. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.04.005.","journal-title":"Semin Nucl Med"},{"issue":"10","key":"7606_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/ph14101005","volume":"14","author":"A Yordanova","year":"2021","unstructured":"Yordanova A, Ahmadzadehfar H. Combination therapies with PRRT. Pharmaceuticals (Basel). 2021;14(10):1005.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"7606_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","volume":"42","author":"R Kashyap","year":"2015","unstructured":"Kashyap R, Hofman MS, Michael M, et al. Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2015;42(2):176\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"7606_CR39","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","volume":"48","author":"S Nicolini","year":"2021","unstructured":"Nicolini S, Bodei L, Bongiovanni A, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48(10):3260\u20137. https:\/\/doi.org\/10.1007\/s00259-021-05236-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7606_CR40","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","volume":"44","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Ahrens H, Feldmann G, et al. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44(5):e329\u201335.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"7606_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","volume":"48","author":"RV Parghane","year":"2021","unstructured":"Parghane RV, Ostwal V, Ramaswamy A, et al. Long-term outcome of sandwich chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2021;48(3):913\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7606_CR42","first-page":"1310","volume":"46","author":"F Forrer","year":"2005","unstructured":"Forrer F, Uusij\u00e4rvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(8):1310\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"7606_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07606-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07606-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:25Z","timestamp":1769834605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07606-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7606"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07606-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the principles of the 1964 Declaration of Helsinki and its subsequent amendments. The study evaluation followed an intention-to-treat approach in all patients, and patients were followed up until death.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}